Pharma & Healthcare
Global Neuromyelitis Optica Drug Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 11, 25
- ID: 304411
- Pages: 140
- Figures: 144
- Views: 20
In 2024, the global market size of Neuromyelitis Optica Drug was estimated to be worth US$ 49.8 million and is forecast to reach approximately US$ 61.1 million by 2031 with a CAGR of 3.0% during the forecast period 2025-2031.
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren"t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.
The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Segment by Type
Glucocorticoids
Immunotherapies
Others
Segment by Application
Acute Attack
Remission Prophylactic Treatment
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Neuromyelitis Optica Drug in global and regional level.
Chapter 3: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Drug revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren"t yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.
The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Drug.
The Neuromyelitis Optica Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuromyelitis Optica Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Pfizer
Fresenius
Teva
Sandoz
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
Segment by Type
Glucocorticoids
Immunotherapies
Others
Segment by Application
Acute Attack
Remission Prophylactic Treatment
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Neuromyelitis Optica Drug in global and regional level.
Chapter 3: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Drug revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
1 Study Coverage
1.1 Neuromyelitis Optica Drug Product Introduction
1.2 Market by Type
1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Neuromyelitis Optica Drug Market Size Estimates and Forecasts
2.2 Neuromyelitis Optica Drug Market Size by Region: 2024 Versus 2031
2.2.1 Global Neuromyelitis Optica Drug Revenue by Region: 2020-2025
2.2.2 Global Neuromyelitis Optica Drug Revenue Forecast by Region (2026-2031)
2.2.3 Global Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Neuromyelitis Optica Drug Revenue by Type (2020-2031)
3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Neuromyelitis Optica Drug Revenue by Application (2020-2031)
3.2.2 Global Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Glucocorticoids of Neuromyelitis Optica Drug Revenue Market Share by Application
3.3.2 Immunotherapies of Neuromyelitis Optica Drug Revenue Market Share by Application
3.3.3 Others of Neuromyelitis Optica Drug Revenue Market Share by Application
4 Global Neuromyelitis Optica Drug by Company
4.1 Global Neuromyelitis Optica Drug Revenue by Company (2020-2025)
4.2 Global Neuromyelitis Optica Drug Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Neuromyelitis Optica Drug Companies around the World: Ranking by Revenue
4.3.2 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Neuromyelitis Optica Drug Companies Headquarters & Product Type
4.4.1 Global Neuromyelitis Optica Drug Companies Headquarters
4.4.2 Date of International Companies Enter into Neuromyelitis Optica Drug Market
4.4.3 Global Neuromyelitis Optica Drug Companies Product & Service
4.4.4 Glucocorticoids Revenue Market Share of Neuromyelitis Optica Drug by Company
4.4.5 Immunotherapies Revenue Market Share of Neuromyelitis Optica Drug by Company
4.4.6 Others Revenue Market Share of Neuromyelitis Optica Drug by Company
4.5 Global Neuromyelitis Optica Drug Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Pfizer
5.1.1 Pfizer Corporation Information
5.1.2 Pfizer Description, Business Overview
5.1.3 Pfizer Neuromyelitis Optica Drug Products Offered
5.1.4 Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.1.5 Pfizer Neuromyelitis Optica Drug Revenue by Product in 2024
5.1.6 Pfizer Neuromyelitis Optica Drug Revenue by Application in 2024
5.1.7 Pfizer Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.1.8 Pfizer Recent Developments
5.2 Fresenius
5.2.1 Fresenius Corporation Information
5.2.2 Fresenius Description, Business Overview
5.2.3 Fresenius Neuromyelitis Optica Drug Products Offered
5.2.4 Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.2.5 Fresenius Neuromyelitis Optica Drug Revenue by Product in 2024
5.2.6 Fresenius Neuromyelitis Optica Drug Revenue by Application in 2024
5.2.7 Fresenius Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.2.8 Fresenius Recent Developments
5.3 Teva
5.3.1 Teva Corporation Information
5.3.2 Teva Description, Business Overview
5.3.3 Teva Neuromyelitis Optica Drug Products Offered
5.3.4 Teva Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.3.5 Teva Neuromyelitis Optica Drug Revenue by Product in 2024
5.3.6 Teva Neuromyelitis Optica Drug Revenue by Application in 2024
5.3.7 Teva Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.3.8 Teva Recent Developments
5.4 Sandoz
5.4.1 Sandoz Corporation Information
5.4.2 Sandoz Description, Business Overview
5.4.3 Sandoz Neuromyelitis Optica Drug Products Offered
5.4.4 Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.4.5 Sandoz Neuromyelitis Optica Drug Revenue by Product in 2024
5.4.6 Sandoz Neuromyelitis Optica Drug Revenue by Application in 2024
5.4.7 Sandoz Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.4.8 Sandoz Recent Developments
5.5 Intas
5.5.1 Intas Corporation Information
5.5.2 Intas Description, Business Overview
5.5.3 Intas Neuromyelitis Optica Drug Products Offered
5.5.4 Intas Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.5.5 Intas Neuromyelitis Optica Drug Revenue by Product in 2024
5.5.6 Intas Neuromyelitis Optica Drug Revenue by Application in 2024
5.5.7 Intas Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.5.8 Intas Recent Developments
5.6 Gyjtrs
5.6.1 Gyjtrs Corporation Information
5.6.2 Gyjtrs Description, Business Overview
5.6.3 Gyjtrs Neuromyelitis Optica Drug Products Offered
5.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.6.5 Gyjtrs Neuromyelitis Optica Drug Revenue by Product in 2024
5.6.6 Gyjtrs Neuromyelitis Optica Drug Revenue by Application in 2024
5.6.7 Gyjtrs Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.6.8 Gyjtrs Recent Developments
5.7 NANG KUANG
5.7.1 NANG KUANG Corporation Information
5.7.2 NANG KUANG Description, Business Overview
5.7.3 NANG KUANG Neuromyelitis Optica Drug Products Offered
5.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.7.5 NANG KUANG Neuromyelitis Optica Drug Revenue by Product in 2024
5.7.6 NANG KUANG Neuromyelitis Optica Drug Revenue by Application in 2024
5.7.7 NANG KUANG Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.7.8 NANG KUANG Recent Developments
5.8 Tianjin Kingyork
5.8.1 Tianjin Kingyork Corporation Information
5.8.2 Tianjin Kingyork Description, Business Overview
5.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products Offered
5.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.8.5 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Product in 2024
5.8.6 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Application in 2024
5.8.7 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.8.8 Tianjin Kingyork Recent Developments
5.9 Baxter
5.9.1 Baxter Corporation Information
5.9.2 Baxter Description, Business Overview
5.9.3 Baxter Neuromyelitis Optica Drug Products Offered
5.9.4 Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.9.5 Baxter Neuromyelitis Optica Drug Revenue by Product in 2024
5.9.6 Baxter Neuromyelitis Optica Drug Revenue by Application in 2024
5.9.7 Baxter Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.9.8 Baxter Recent Developments
5.10 CSL
5.10.1 CSL Corporation Information
5.10.2 CSL Description, Business Overview
5.10.3 CSL Neuromyelitis Optica Drug Products Offered
5.10.4 CSL Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.10.5 CSL Neuromyelitis Optica Drug Revenue by Product in 2024
5.10.6 CSL Neuromyelitis Optica Drug Revenue by Application in 2024
5.10.7 CSL Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.10.8 CSL Recent Developments
5.11 Grifols
5.11.1 Grifols Corporation Information
5.11.2 Grifols Description, Business Overview
5.11.3 Grifols Neuromyelitis Optica Drug Products Offered
5.11.4 Grifols Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.11.5 Grifols Neuromyelitis Optica Drug Revenue by Product in 2024
5.11.6 Grifols Neuromyelitis Optica Drug Revenue by Application in 2024
5.11.7 Grifols Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.11.8 Grifols Recent Developments
5.12 Octapharma
5.12.1 Octapharma Corporation Information
5.12.2 Octapharma Description, Business Overview
5.12.3 Octapharma Neuromyelitis Optica Drug Products Offered
5.12.4 Octapharma Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.12.5 Octapharma Neuromyelitis Optica Drug Revenue by Product in 2024
5.12.6 Octapharma Neuromyelitis Optica Drug Revenue by Application in 2024
5.12.7 Octapharma Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.12.8 Octapharma Recent Developments
5.13 CBOP
5.13.1 CBOP Corporation Information
5.13.2 CBOP Description, Business Overview
5.13.3 CBOP Neuromyelitis Optica Drug Products Offered
5.13.4 CBOP Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.13.5 CBOP Neuromyelitis Optica Drug Revenue by Product in 2024
5.13.6 CBOP Neuromyelitis Optica Drug Revenue by Application in 2024
5.13.7 CBOP Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.13.8 CBOP Recent Developments
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
6.2 North America Neuromyelitis Optica Drug Market Facts & Figures by Country (2020-2031)
6.3 North America Neuromyelitis Optica Drug Revenue by Type (2020-2025)
6.4 North America Neuromyelitis Optica Drug Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Neuromyelitis Optica Drug Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Neuromyelitis Optica Drug Revenue by Type (2020-2025)
7.4 Asia-Pacific Neuromyelitis Optica Drug Revenue by Application (2020-2025)
8 Europe
8.1 Europe Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
8.2 Europe Neuromyelitis Optica Drug Market Facts & Figures by Country (2020-2031)
8.3 Europe Neuromyelitis Optica Drug Revenue by Type (2020-2025)
8.4 Europe Neuromyelitis Optica Drug Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
9.2 Latin America Neuromyelitis Optica Drug Market Facts & Figures by Country (2020-2031)
9.3 Latin America Neuromyelitis Optica Drug Revenue by Type (2020-2025)
9.4 Latin America Neuromyelitis Optica Drug Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Neuromyelitis Optica Drug Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Neuromyelitis Optica Drug Revenue by Type (2020-2025)
10.4 Middle East and Africa Neuromyelitis Optica Drug Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Neuromyelitis Optica Drug Supply Chain Analysis
11.2 Neuromyelitis Optica Drug Key Raw Materials and Upstream Suppliers
11.3 Neuromyelitis Optica Drug Clients Analysis
11.4 Neuromyelitis Optica Drug Sales Channel and Sales Model Analysis
11.4.1 Neuromyelitis Optica Drug Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Neuromyelitis Optica Drug Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Neuromyelitis Optica Drug Distributors
12 Neuromyelitis Optica Drug Market Dynamics
12.1 Neuromyelitis Optica Drug Industry Trends
12.2 Neuromyelitis Optica Drug Market Drivers
12.3 Neuromyelitis Optica Drug Market Challenges
12.4 Neuromyelitis Optica Drug Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Neuromyelitis Optica Drug Product Introduction
1.2 Market by Type
1.2.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Glucocorticoids
1.2.3 Immunotherapies
1.2.4 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Acute Attack
1.3.3 Remission Prophylactic Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Neuromyelitis Optica Drug Market Size Estimates and Forecasts
2.2 Neuromyelitis Optica Drug Market Size by Region: 2024 Versus 2031
2.2.1 Global Neuromyelitis Optica Drug Revenue by Region: 2020-2025
2.2.2 Global Neuromyelitis Optica Drug Revenue Forecast by Region (2026-2031)
2.2.3 Global Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Neuromyelitis Optica Drug Revenue by Type (2020-2031)
3.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Neuromyelitis Optica Drug Revenue by Application (2020-2031)
3.2.2 Global Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Glucocorticoids of Neuromyelitis Optica Drug Revenue Market Share by Application
3.3.2 Immunotherapies of Neuromyelitis Optica Drug Revenue Market Share by Application
3.3.3 Others of Neuromyelitis Optica Drug Revenue Market Share by Application
4 Global Neuromyelitis Optica Drug by Company
4.1 Global Neuromyelitis Optica Drug Revenue by Company (2020-2025)
4.2 Global Neuromyelitis Optica Drug Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key Neuromyelitis Optica Drug Companies around the World: Ranking by Revenue
4.3.2 Global Neuromyelitis Optica Drug Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global Neuromyelitis Optica Drug Companies Headquarters & Product Type
4.4.1 Global Neuromyelitis Optica Drug Companies Headquarters
4.4.2 Date of International Companies Enter into Neuromyelitis Optica Drug Market
4.4.3 Global Neuromyelitis Optica Drug Companies Product & Service
4.4.4 Glucocorticoids Revenue Market Share of Neuromyelitis Optica Drug by Company
4.4.5 Immunotherapies Revenue Market Share of Neuromyelitis Optica Drug by Company
4.4.6 Others Revenue Market Share of Neuromyelitis Optica Drug by Company
4.5 Global Neuromyelitis Optica Drug Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Pfizer
5.1.1 Pfizer Corporation Information
5.1.2 Pfizer Description, Business Overview
5.1.3 Pfizer Neuromyelitis Optica Drug Products Offered
5.1.4 Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.1.5 Pfizer Neuromyelitis Optica Drug Revenue by Product in 2024
5.1.6 Pfizer Neuromyelitis Optica Drug Revenue by Application in 2024
5.1.7 Pfizer Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.1.8 Pfizer Recent Developments
5.2 Fresenius
5.2.1 Fresenius Corporation Information
5.2.2 Fresenius Description, Business Overview
5.2.3 Fresenius Neuromyelitis Optica Drug Products Offered
5.2.4 Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.2.5 Fresenius Neuromyelitis Optica Drug Revenue by Product in 2024
5.2.6 Fresenius Neuromyelitis Optica Drug Revenue by Application in 2024
5.2.7 Fresenius Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.2.8 Fresenius Recent Developments
5.3 Teva
5.3.1 Teva Corporation Information
5.3.2 Teva Description, Business Overview
5.3.3 Teva Neuromyelitis Optica Drug Products Offered
5.3.4 Teva Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.3.5 Teva Neuromyelitis Optica Drug Revenue by Product in 2024
5.3.6 Teva Neuromyelitis Optica Drug Revenue by Application in 2024
5.3.7 Teva Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.3.8 Teva Recent Developments
5.4 Sandoz
5.4.1 Sandoz Corporation Information
5.4.2 Sandoz Description, Business Overview
5.4.3 Sandoz Neuromyelitis Optica Drug Products Offered
5.4.4 Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.4.5 Sandoz Neuromyelitis Optica Drug Revenue by Product in 2024
5.4.6 Sandoz Neuromyelitis Optica Drug Revenue by Application in 2024
5.4.7 Sandoz Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.4.8 Sandoz Recent Developments
5.5 Intas
5.5.1 Intas Corporation Information
5.5.2 Intas Description, Business Overview
5.5.3 Intas Neuromyelitis Optica Drug Products Offered
5.5.4 Intas Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.5.5 Intas Neuromyelitis Optica Drug Revenue by Product in 2024
5.5.6 Intas Neuromyelitis Optica Drug Revenue by Application in 2024
5.5.7 Intas Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.5.8 Intas Recent Developments
5.6 Gyjtrs
5.6.1 Gyjtrs Corporation Information
5.6.2 Gyjtrs Description, Business Overview
5.6.3 Gyjtrs Neuromyelitis Optica Drug Products Offered
5.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.6.5 Gyjtrs Neuromyelitis Optica Drug Revenue by Product in 2024
5.6.6 Gyjtrs Neuromyelitis Optica Drug Revenue by Application in 2024
5.6.7 Gyjtrs Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.6.8 Gyjtrs Recent Developments
5.7 NANG KUANG
5.7.1 NANG KUANG Corporation Information
5.7.2 NANG KUANG Description, Business Overview
5.7.3 NANG KUANG Neuromyelitis Optica Drug Products Offered
5.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.7.5 NANG KUANG Neuromyelitis Optica Drug Revenue by Product in 2024
5.7.6 NANG KUANG Neuromyelitis Optica Drug Revenue by Application in 2024
5.7.7 NANG KUANG Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.7.8 NANG KUANG Recent Developments
5.8 Tianjin Kingyork
5.8.1 Tianjin Kingyork Corporation Information
5.8.2 Tianjin Kingyork Description, Business Overview
5.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Products Offered
5.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.8.5 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Product in 2024
5.8.6 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Application in 2024
5.8.7 Tianjin Kingyork Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.8.8 Tianjin Kingyork Recent Developments
5.9 Baxter
5.9.1 Baxter Corporation Information
5.9.2 Baxter Description, Business Overview
5.9.3 Baxter Neuromyelitis Optica Drug Products Offered
5.9.4 Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.9.5 Baxter Neuromyelitis Optica Drug Revenue by Product in 2024
5.9.6 Baxter Neuromyelitis Optica Drug Revenue by Application in 2024
5.9.7 Baxter Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.9.8 Baxter Recent Developments
5.10 CSL
5.10.1 CSL Corporation Information
5.10.2 CSL Description, Business Overview
5.10.3 CSL Neuromyelitis Optica Drug Products Offered
5.10.4 CSL Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.10.5 CSL Neuromyelitis Optica Drug Revenue by Product in 2024
5.10.6 CSL Neuromyelitis Optica Drug Revenue by Application in 2024
5.10.7 CSL Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.10.8 CSL Recent Developments
5.11 Grifols
5.11.1 Grifols Corporation Information
5.11.2 Grifols Description, Business Overview
5.11.3 Grifols Neuromyelitis Optica Drug Products Offered
5.11.4 Grifols Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.11.5 Grifols Neuromyelitis Optica Drug Revenue by Product in 2024
5.11.6 Grifols Neuromyelitis Optica Drug Revenue by Application in 2024
5.11.7 Grifols Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.11.8 Grifols Recent Developments
5.12 Octapharma
5.12.1 Octapharma Corporation Information
5.12.2 Octapharma Description, Business Overview
5.12.3 Octapharma Neuromyelitis Optica Drug Products Offered
5.12.4 Octapharma Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.12.5 Octapharma Neuromyelitis Optica Drug Revenue by Product in 2024
5.12.6 Octapharma Neuromyelitis Optica Drug Revenue by Application in 2024
5.12.7 Octapharma Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.12.8 Octapharma Recent Developments
5.13 CBOP
5.13.1 CBOP Corporation Information
5.13.2 CBOP Description, Business Overview
5.13.3 CBOP Neuromyelitis Optica Drug Products Offered
5.13.4 CBOP Neuromyelitis Optica Drug Revenue and Gross Margin (2020-2025)
5.13.5 CBOP Neuromyelitis Optica Drug Revenue by Product in 2024
5.13.6 CBOP Neuromyelitis Optica Drug Revenue by Application in 2024
5.13.7 CBOP Neuromyelitis Optica Drug Revenue by Geographic Area in 2024
5.13.8 CBOP Recent Developments
6 North America
6.1 North America Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
6.2 North America Neuromyelitis Optica Drug Market Facts & Figures by Country (2020-2031)
6.3 North America Neuromyelitis Optica Drug Revenue by Type (2020-2025)
6.4 North America Neuromyelitis Optica Drug Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Neuromyelitis Optica Drug Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific Neuromyelitis Optica Drug Revenue by Type (2020-2025)
7.4 Asia-Pacific Neuromyelitis Optica Drug Revenue by Application (2020-2025)
8 Europe
8.1 Europe Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
8.2 Europe Neuromyelitis Optica Drug Market Facts & Figures by Country (2020-2031)
8.3 Europe Neuromyelitis Optica Drug Revenue by Type (2020-2025)
8.4 Europe Neuromyelitis Optica Drug Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
9.2 Latin America Neuromyelitis Optica Drug Market Facts & Figures by Country (2020-2031)
9.3 Latin America Neuromyelitis Optica Drug Revenue by Type (2020-2025)
9.4 Latin America Neuromyelitis Optica Drug Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Neuromyelitis Optica Drug Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Neuromyelitis Optica Drug Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa Neuromyelitis Optica Drug Revenue by Type (2020-2025)
10.4 Middle East and Africa Neuromyelitis Optica Drug Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Neuromyelitis Optica Drug Supply Chain Analysis
11.2 Neuromyelitis Optica Drug Key Raw Materials and Upstream Suppliers
11.3 Neuromyelitis Optica Drug Clients Analysis
11.4 Neuromyelitis Optica Drug Sales Channel and Sales Model Analysis
11.4.1 Neuromyelitis Optica Drug Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Neuromyelitis Optica Drug Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Neuromyelitis Optica Drug Distributors
12 Neuromyelitis Optica Drug Market Dynamics
12.1 Neuromyelitis Optica Drug Industry Trends
12.2 Neuromyelitis Optica Drug Market Drivers
12.3 Neuromyelitis Optica Drug Market Challenges
12.4 Neuromyelitis Optica Drug Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Neuromyelitis Optica Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Neuromyelitis Optica Drug Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Neuromyelitis Optica Drug Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Neuromyelitis Optica Drug Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 11. Neuromyelitis Optica Drug Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Neuromyelitis Optica Drug Players by Revenue (US$ Million) in 2024
Table 13. Global Neuromyelitis Optica Drug Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Table 15. Global Neuromyelitis Optica Drug Companies Headquarters
Table 16. Date of International Companies Enter into Neuromyelitis Optica Drug Market
Table 17. Global Neuromyelitis Optica Drug Companies Product & Service
Table 18. Global Neuromyelitis Optica Drug Mergers & Acquisitions, Expansion Plans
Table 19. Pfizer Corporation Information
Table 20. Pfizer Description and Business Overview
Table 21. Pfizer Neuromyelitis Optica Drug Product
Table 22. Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 24. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 25. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 26. Pfizer Recent Developments
Table 27. Fresenius Corporation Information
Table 28. Fresenius Description and Business Overview
Table 29. Fresenius Neuromyelitis Optica Drug Product
Table 30. Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 32. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 33. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 34. Fresenius Recent Developments
Table 35. Teva Corporation Information
Table 36. Teva Description and Business Overview
Table 37. Teva Neuromyelitis Optica Drug Product
Table 38. Teva Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Teva Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 40. Teva Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 41. Teva Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 42. Teva Recent Developments
Table 43. Sandoz Corporation Information
Table 44. Sandoz Description and Business Overview
Table 45. Sandoz Neuromyelitis Optica Drug Product
Table 46. Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 48. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 49. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 50. Sandoz Recent Developments
Table 51. Intas Corporation Information
Table 52. Intas Description and Business Overview
Table 53. Intas Neuromyelitis Optica Drug Product
Table 54. Intas Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Intas Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 56. Intas Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 57. Intas Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 58. Intas Recent Developments
Table 59. Gyjtrs Corporation Information
Table 60. Gyjtrs Description and Business Overview
Table 61. Gyjtrs Neuromyelitis Optica Drug Product
Table 62. Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 64. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 65. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 66. Gyjtrs Recent Developments
Table 67. NANG KUANG Corporation Information
Table 68. NANG KUANG Description and Business Overview
Table 69. NANG KUANG Neuromyelitis Optica Drug Product
Table 70. NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 72. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 73. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 74. NANG KUANG Recent Developments
Table 75. Tianjin Kingyork Corporation Information
Table 76. Tianjin Kingyork Description and Business Overview
Table 77. Tianjin Kingyork Neuromyelitis Optica Drug Product
Table 78. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 80. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 81. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 82. Tianjin Kingyork Recent Developments
Table 83. Baxter Corporation Information
Table 84. Baxter Description and Business Overview
Table 85. Baxter Neuromyelitis Optica Drug Product
Table 86. Baxter Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 88. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 89. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 90. Baxter Recent Developments
Table 91. CSL Corporation Information
Table 92. CSL Description and Business Overview
Table 93. CSL Neuromyelitis Optica Drug Product
Table 94. CSL Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. CSL Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 96. CSL Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 97. CSL Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 98. CSL Recent Developments
Table 99. Grifols Corporation Information
Table 100. Grifols Description and Business Overview
Table 101. Grifols Neuromyelitis Optica Drug Product
Table 102. Grifols Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 104. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 105. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 106. Grifols Recent Developments
Table 107. Octapharma Corporation Information
Table 108. Octapharma Description and Business Overview
Table 109. Octapharma Neuromyelitis Optica Drug Product
Table 110. Octapharma Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 112. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 113. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 114. Octapharma Recent Developments
Table 115. CBOP Corporation Information
Table 116. CBOP Description and Business Overview
Table 117. CBOP Neuromyelitis Optica Drug Product
Table 118. CBOP Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 120. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 121. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 122. CBOP Recent Developments
Table 123. North America Neuromyelitis Optica Drug Revenue by Country (2020-2025) & (US$ Million)
Table 124. North America Neuromyelitis Optica Drug Revenue by Country (2026-2031) & (US$ Million)
Table 125. North America Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 126. North America Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 127. Asia-Pacific Neuromyelitis Optica Drug Revenue by Region (2020-2025) & (US$ Million)
Table 128. Asia-Pacific Neuromyelitis Optica Drug Revenue by Region (2026-2031) & (US$ Million)
Table 129. Asia-Pacific Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 130. Asia-Pacific Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 131. Europe Neuromyelitis Optica Drug Revenue by Country (2020-2025) & (US$ Million)
Table 132. Europe Neuromyelitis Optica Drug Revenue by Country (2026-2031) & (US$ Million)
Table 133. Europe Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 134. Europe Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 135. Latin America Neuromyelitis Optica Drug Revenue by Country (2020-2025) & (US$ Million)
Table 136. Latin America Neuromyelitis Optica Drug Revenue by Country (2026-2031) & (US$ Million)
Table 137. Latin America Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 138. Latin America Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 139. Middle East and Africa Neuromyelitis Optica Drug Revenue by Country (2020-2025) & (US$ Million)
Table 140. Middle East and Africa Neuromyelitis Optica Drug Revenue by Country (2026-2031) & (US$ Million)
Table 141. Middle East and Africa Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 142. Middle East and Africa Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 143. Neuromyelitis Optica Drug Key Raw Materials, Industry Status and Trend
Table 144. Neuromyelitis Optica Drug Key Raw Materials and Upstream Suppliers
Table 145. Neuromyelitis Optica Drug Clients Status and Trend
Table 146. Neuromyelitis Optica Drug Typical Clients
Table 147. Neuromyelitis Optica Drug Distributors
Table 148. Neuromyelitis Optica Drug Market Trends
Table 149. Neuromyelitis Optica Drug Market Drivers
Table 150. Neuromyelitis Optica Drug Market Challenges
Table 151. Neuromyelitis Optica Drug Market Restraints
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuromyelitis Optica Drug Product Picture
Figure 2. Global Neuromyelitis Optica Drug Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Neuromyelitis Optica Drug Revenue Market Share by Type in 2024 & 2031
Figure 4. Glucocorticoids Product Picture
Figure 5. Immunotherapies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Neuromyelitis Optica Drug Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Neuromyelitis Optica Drug Revenue Market Share by Application in 2024 & 2031
Figure 9. Acute Attack
Figure 10. Remission Prophylactic Treatment
Figure 11. Neuromyelitis Optica Drug Report Years Considered
Figure 12. Global Neuromyelitis Optica Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Neuromyelitis Optica Drug Market Size (2020-2031) & (US$ Million)
Figure 14. Global Neuromyelitis Optica Drug Market Size Market Share by Region: 2024 Versus 2031
Figure 15. Global Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2031)
Figure 16. Global Neuromyelitis Optica Drug Revenue Market Share Forecast by Type (2020-2031)
Figure 17. Global Neuromyelitis Optica Drug Revenue Market Share Forecast by Application (2020-2031)
Figure 18. Glucocorticoids of Neuromyelitis Optica Drug Revenue Market Share by Application, 2024 VS 2031
Figure 19. Immunotherapies of Neuromyelitis Optica Drug Revenue Market Share by Application, 2024 VS 2031
Figure 20. Others of Neuromyelitis Optica Drug Revenue Market Share by Application, 2024 VS 2031
Figure 21. Neuromyelitis Optica Drug Revenue Share by Company (2024)
Figure 22. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Glucocorticoids Revenue Proportion by Company in 2024
Figure 24. Immunotherapies Revenue Proportion by Company in 2024
Figure 25. Others Revenue Proportion by Company in 2024
Figure 26. North America Neuromyelitis Optica Drug Revenue 2020-2031 (US$ Million)
Figure 27. North America Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 28. North America Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 29. Asia-Pacific Neuromyelitis Optica Drug Revenue 2020-2031 (US$ Million)
Figure 30. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2031)
Figure 31. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 32. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 33. Europe Neuromyelitis Optica Drug Revenue Growth Rate 2020-2031 (US$ Million)
Figure 34. Europe Neuromyelitis Optica Drug Revenue Market Share by Country (2020-2031)
Figure 35. Europe Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 36. Europe Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 37. Latin America Neuromyelitis Optica Drug Revenue Growth Rate 2020-2031 (US$ Million)
Figure 38. Latin America Neuromyelitis Optica Drug Revenue Market Share by Country (2020-2031)
Figure 39. Latin America Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 40. Latin America Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 41. Middle East and Africa Neuromyelitis Optica Drug Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Country (2020-2031)
Figure 43. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 44. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 45. Neuromyelitis Optica Drug Supply Chain (Upstream and Downstream Market)
Figure 46. Global Production Market Share of Neuromyelitis Optica Drug Raw Materials by Region in 2024
Figure 47. Neuromyelitis Optica Drug Distribution Channels
Figure 48. Global Neuromyelitis Optica Drug Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 49. Global Neuromyelitis Optica Drug Percentage 2020-2031: Online Sales VS Offline Sales
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Neuromyelitis Optica Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Neuromyelitis Optica Drug Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Neuromyelitis Optica Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Neuromyelitis Optica Drug Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global Neuromyelitis Optica Drug Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global Neuromyelitis Optica Drug Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. Neuromyelitis Optica Drug Revenue by Company (2020-2025) & (US$ Million)
Table 11. Neuromyelitis Optica Drug Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top Neuromyelitis Optica Drug Players by Revenue (US$ Million) in 2024
Table 13. Global Neuromyelitis Optica Drug Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Drug as of 2024)
Table 15. Global Neuromyelitis Optica Drug Companies Headquarters
Table 16. Date of International Companies Enter into Neuromyelitis Optica Drug Market
Table 17. Global Neuromyelitis Optica Drug Companies Product & Service
Table 18. Global Neuromyelitis Optica Drug Mergers & Acquisitions, Expansion Plans
Table 19. Pfizer Corporation Information
Table 20. Pfizer Description and Business Overview
Table 21. Pfizer Neuromyelitis Optica Drug Product
Table 22. Pfizer Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 24. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 25. Pfizer Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 26. Pfizer Recent Developments
Table 27. Fresenius Corporation Information
Table 28. Fresenius Description and Business Overview
Table 29. Fresenius Neuromyelitis Optica Drug Product
Table 30. Fresenius Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 32. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 33. Fresenius Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 34. Fresenius Recent Developments
Table 35. Teva Corporation Information
Table 36. Teva Description and Business Overview
Table 37. Teva Neuromyelitis Optica Drug Product
Table 38. Teva Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Teva Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 40. Teva Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 41. Teva Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 42. Teva Recent Developments
Table 43. Sandoz Corporation Information
Table 44. Sandoz Description and Business Overview
Table 45. Sandoz Neuromyelitis Optica Drug Product
Table 46. Sandoz Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 48. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 49. Sandoz Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 50. Sandoz Recent Developments
Table 51. Intas Corporation Information
Table 52. Intas Description and Business Overview
Table 53. Intas Neuromyelitis Optica Drug Product
Table 54. Intas Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Intas Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 56. Intas Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 57. Intas Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 58. Intas Recent Developments
Table 59. Gyjtrs Corporation Information
Table 60. Gyjtrs Description and Business Overview
Table 61. Gyjtrs Neuromyelitis Optica Drug Product
Table 62. Gyjtrs Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 64. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 65. Gyjtrs Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 66. Gyjtrs Recent Developments
Table 67. NANG KUANG Corporation Information
Table 68. NANG KUANG Description and Business Overview
Table 69. NANG KUANG Neuromyelitis Optica Drug Product
Table 70. NANG KUANG Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 72. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 73. NANG KUANG Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 74. NANG KUANG Recent Developments
Table 75. Tianjin Kingyork Corporation Information
Table 76. Tianjin Kingyork Description and Business Overview
Table 77. Tianjin Kingyork Neuromyelitis Optica Drug Product
Table 78. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 80. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 81. Tianjin Kingyork Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 82. Tianjin Kingyork Recent Developments
Table 83. Baxter Corporation Information
Table 84. Baxter Description and Business Overview
Table 85. Baxter Neuromyelitis Optica Drug Product
Table 86. Baxter Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 88. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 89. Baxter Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 90. Baxter Recent Developments
Table 91. CSL Corporation Information
Table 92. CSL Description and Business Overview
Table 93. CSL Neuromyelitis Optica Drug Product
Table 94. CSL Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. CSL Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 96. CSL Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 97. CSL Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 98. CSL Recent Developments
Table 99. Grifols Corporation Information
Table 100. Grifols Description and Business Overview
Table 101. Grifols Neuromyelitis Optica Drug Product
Table 102. Grifols Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 104. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 105. Grifols Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 106. Grifols Recent Developments
Table 107. Octapharma Corporation Information
Table 108. Octapharma Description and Business Overview
Table 109. Octapharma Neuromyelitis Optica Drug Product
Table 110. Octapharma Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 112. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 113. Octapharma Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 114. Octapharma Recent Developments
Table 115. CBOP Corporation Information
Table 116. CBOP Description and Business Overview
Table 117. CBOP Neuromyelitis Optica Drug Product
Table 118. CBOP Neuromyelitis Optica Drug Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Product in 2024
Table 120. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Application in 2024
Table 121. CBOP Revenue Proportion of Neuromyelitis Optica Drug by Geographic Area in 2024
Table 122. CBOP Recent Developments
Table 123. North America Neuromyelitis Optica Drug Revenue by Country (2020-2025) & (US$ Million)
Table 124. North America Neuromyelitis Optica Drug Revenue by Country (2026-2031) & (US$ Million)
Table 125. North America Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 126. North America Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 127. Asia-Pacific Neuromyelitis Optica Drug Revenue by Region (2020-2025) & (US$ Million)
Table 128. Asia-Pacific Neuromyelitis Optica Drug Revenue by Region (2026-2031) & (US$ Million)
Table 129. Asia-Pacific Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 130. Asia-Pacific Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 131. Europe Neuromyelitis Optica Drug Revenue by Country (2020-2025) & (US$ Million)
Table 132. Europe Neuromyelitis Optica Drug Revenue by Country (2026-2031) & (US$ Million)
Table 133. Europe Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 134. Europe Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 135. Latin America Neuromyelitis Optica Drug Revenue by Country (2020-2025) & (US$ Million)
Table 136. Latin America Neuromyelitis Optica Drug Revenue by Country (2026-2031) & (US$ Million)
Table 137. Latin America Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 138. Latin America Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 139. Middle East and Africa Neuromyelitis Optica Drug Revenue by Country (2020-2025) & (US$ Million)
Table 140. Middle East and Africa Neuromyelitis Optica Drug Revenue by Country (2026-2031) & (US$ Million)
Table 141. Middle East and Africa Neuromyelitis Optica Drug Revenue by Type (2020-2025) & (US$ Million)
Table 142. Middle East and Africa Neuromyelitis Optica Drug Revenue by Application (2020-2025) & (US$ Million)
Table 143. Neuromyelitis Optica Drug Key Raw Materials, Industry Status and Trend
Table 144. Neuromyelitis Optica Drug Key Raw Materials and Upstream Suppliers
Table 145. Neuromyelitis Optica Drug Clients Status and Trend
Table 146. Neuromyelitis Optica Drug Typical Clients
Table 147. Neuromyelitis Optica Drug Distributors
Table 148. Neuromyelitis Optica Drug Market Trends
Table 149. Neuromyelitis Optica Drug Market Drivers
Table 150. Neuromyelitis Optica Drug Market Challenges
Table 151. Neuromyelitis Optica Drug Market Restraints
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuromyelitis Optica Drug Product Picture
Figure 2. Global Neuromyelitis Optica Drug Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Neuromyelitis Optica Drug Revenue Market Share by Type in 2024 & 2031
Figure 4. Glucocorticoids Product Picture
Figure 5. Immunotherapies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Neuromyelitis Optica Drug Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Neuromyelitis Optica Drug Revenue Market Share by Application in 2024 & 2031
Figure 9. Acute Attack
Figure 10. Remission Prophylactic Treatment
Figure 11. Neuromyelitis Optica Drug Report Years Considered
Figure 12. Global Neuromyelitis Optica Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Neuromyelitis Optica Drug Market Size (2020-2031) & (US$ Million)
Figure 14. Global Neuromyelitis Optica Drug Market Size Market Share by Region: 2024 Versus 2031
Figure 15. Global Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2031)
Figure 16. Global Neuromyelitis Optica Drug Revenue Market Share Forecast by Type (2020-2031)
Figure 17. Global Neuromyelitis Optica Drug Revenue Market Share Forecast by Application (2020-2031)
Figure 18. Glucocorticoids of Neuromyelitis Optica Drug Revenue Market Share by Application, 2024 VS 2031
Figure 19. Immunotherapies of Neuromyelitis Optica Drug Revenue Market Share by Application, 2024 VS 2031
Figure 20. Others of Neuromyelitis Optica Drug Revenue Market Share by Application, 2024 VS 2031
Figure 21. Neuromyelitis Optica Drug Revenue Share by Company (2024)
Figure 22. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. Glucocorticoids Revenue Proportion by Company in 2024
Figure 24. Immunotherapies Revenue Proportion by Company in 2024
Figure 25. Others Revenue Proportion by Company in 2024
Figure 26. North America Neuromyelitis Optica Drug Revenue 2020-2031 (US$ Million)
Figure 27. North America Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 28. North America Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 29. Asia-Pacific Neuromyelitis Optica Drug Revenue 2020-2031 (US$ Million)
Figure 30. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Region (2020-2031)
Figure 31. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 32. Asia-Pacific Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 33. Europe Neuromyelitis Optica Drug Revenue Growth Rate 2020-2031 (US$ Million)
Figure 34. Europe Neuromyelitis Optica Drug Revenue Market Share by Country (2020-2031)
Figure 35. Europe Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 36. Europe Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 37. Latin America Neuromyelitis Optica Drug Revenue Growth Rate 2020-2031 (US$ Million)
Figure 38. Latin America Neuromyelitis Optica Drug Revenue Market Share by Country (2020-2031)
Figure 39. Latin America Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 40. Latin America Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 41. Middle East and Africa Neuromyelitis Optica Drug Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Country (2020-2031)
Figure 43. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Type (2020-2025)
Figure 44. Middle East and Africa Neuromyelitis Optica Drug Revenue Market Share by Application (2020-2025)
Figure 45. Neuromyelitis Optica Drug Supply Chain (Upstream and Downstream Market)
Figure 46. Global Production Market Share of Neuromyelitis Optica Drug Raw Materials by Region in 2024
Figure 47. Neuromyelitis Optica Drug Distribution Channels
Figure 48. Global Neuromyelitis Optica Drug Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 49. Global Neuromyelitis Optica Drug Percentage 2020-2031: Online Sales VS Offline Sales
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232